November 24, 2025

AstraZeneca Onshores Rare Disease Portfolio as Part of $50B US Investment Pledge

6 hours ago talkbio0Tagged AstraZeneca, expansion, Infrequent, Investments, Maryland (geographic location), onshoring, pledge, portfolio, R&D, U.S., Virginia facility

AstraZeneca; rare disease portfolio; onshoring; US investment; biomanufacturing; $50 billion pledge; Virginia facility; Maryland investment; R&D expansion

Sandoz Launches Afqlir (Aflibercept) in Europe, Increasing Access to Affordable Retinal Disease Treatment

9 hours ago talkbio0Tagged affordable treatment, aflibercept, Afqlir, Age related macular degeneration, anti-VEGF therapies, Biosimilars, Blindness, Europe, European Commission approval, Exudative age-related macular degeneration, Eylea, Neovascular, Retinal Diseases, sandoz

Sandoz; Afqlir; aflibercept; biosimilar; retinal diseases; neovascular age-related macular degeneration (nAMD); European Commission approval; Eylea; anti-VEGF therapies; affordable treatment; vision loss; Europe

As Drug Resistance Rises, GramEye and GSK Advance New AI-Led Infectious Disease Research

19 hours ago talkbio0Tagged AI-driven, Antibiotics, Antimicrobial Resistance, Clinical Trials, Communicable Diseases, Drug Discovery, Gram-negative bacteria, GramEye, Mycoses, research, SmithKline Beecham, Staphylococcus aureus, superbugs

antimicrobial resistance (AMR); GramEye; GSK; AI-driven drug discovery; Gram-negative bacteria; Staphylococcus aureus; fungal infections; novel antibiotics; superbugs; infectious disease research; clinical trials